Cyfuse Biomedical K.K Valuation

Is 4892 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4892 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4892's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4892's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4892?

Key metric: As 4892 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 4892. This is calculated by dividing 4892's market cap by their current book value.
What is 4892's PB Ratio?
PB Ratio	1.3x
Book	JP¥2.93b
Market Cap	JP¥3.82b

4892 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	20.3x
Enterprise Value/EBITDA	-1.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 4892's PB Ratio compare to its peers?

The above table shows the PB ratio for 4892 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3.6x
6090 Human Metabolome Technologies	2x	n/a	JP¥3.6b
4570 Immuno-Biological Laboratories	3.5x	n/a	JP¥4.7b
2397 DNA Chip Research	6.8x	n/a	JP¥4.8b
4572 Carna Biosciences	2.2x	n/a	JP¥5.9b
4892 Cyfuse Biomedical K.K	1.3x	n/a	JP¥3.8b

Price-To-Book vs Peers: 4892 is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (3.6x).

Price to Book Ratio vs Industry

How does 4892's PB Ratio compare vs other companies in the Asian Life Sciences Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 4892 is good value based on its Price-To-Book Ratio (1.3x) compared to the Asian Life Sciences industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 4892's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4892 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4892's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Kyowa Kirin

JP¥1.3t

Engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally.

4151

JP¥2,545.00

-0.9%

3.4%

Tsumura

JP¥366.2b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,823.00

-1.2%

77.6%

ASKA Pharmaceutical HoldingsLtd

JP¥57.7b

Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.

4886

JP¥2,036.00

-1.6%

13.2%